UnknownNot Applicable

Treatment of Intraocular Retinoblastoma

1,600 participantsStarted 2022-06-20

Plain-language summary

This study compares the effects of balloon technology and microcatheter technology on the eye protection rate of neuroblastoma

Age range1 Year – 18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

✓. 1 year old \<age ≤ 18 years old;
✓. After biopsy, histopathology and immunohistochemistry tests refer to the COG recommended neuroblastoma diagnostic criteria, pathological classification (INPC), and international neuroblastoma staging (INSS)
✓. Patients who were diagnosed with RB for the first time or received chemotherapy in our hospital for the first time after diagnosis
✓. ECOG scale (ECOG-PS) ≤ 2;

✕. No antibiotics and no gastrointestinal surgery within 3 months.
✕. Patients with autoimmune diseases;
✕. Patients with immunodeficiency;
✕. Patients who have been treated for relapsed/refractory diseases; relapsed NB is the appearance of new lesions at the primary site or other sites 4 weeks after the multidisciplinary comprehensive treatment reaches CR. Refractory NB is defined as induced by 2 to 4 courses of treatment The post-effect evaluation is progression disease (PD) during chemotherapy;
✕. Multiple organ failure;
✕. Uncontrolled infection and diarrhea

Overall success rate

Timeframe: 1 year

Second tumor rate

Timeframe: 1 year

NCT IDNCT05028270

SponsorXinhua Hospital, Shanghai Jiao Tong University School of Medicine

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2022-10-01

Chaohui Jin, Phd, MD